Key facts
- This page summarizes Sebastien Hazard's Form 4 filing for Imunon, Inc. (IMNN).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 11 Dec 2023, 16:07.
Sebastien Hazard - 07 Dec 2023 Form 4 Insider Report for Imunon, Inc. (IMNN)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- IMNN
- Reported as of
- 07 Dec 2023
- Net transaction value
- $0
- Reporting owner signature
- /s/ Sebastien Hazard, by Jeffrey Church, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Sebastien Hazard filed Form 4 for Imunon, Inc. (IMNN) on 11 Dec 2023.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMNN
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +20,000
- Change %
- Price
- $0.000000
- Shares after
- 20,000
- Date
- 07 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMNN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +80,000
- Change %
- Price
- $0.000000
- Shares after
- 80,000
- Date
- 07 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 80,000
- Exercise price
- $0.8800
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents grant of restricted stock, which vests on December 11, 2024.
Footnote F2
Represents grant of stock option, which vests with respect to 25% of the shares on December 11, 2024, and the remaining 75% in equal quarterly installments thereafter such that the stock option will be fully vested and exercisable on the fourth anniversary of December 11, 2023.